← Issue №15/ week of Oct 11, 2026/Hepatology

First-line durvalumab and tremelimumab in poor-prognosis unresectable hepatocellular carcinoma: Phase IIIb single-arm SIERRA study.

From GI Signals issue №15: what this paper found, what it changes, and where it sits against the current standard of care, reviewed by Simon Mathews, MD.

Hepatology rct · n=111 · Oct 6, 2026 · J Hepatology · IF 40.1

First-line durvalumab and tremelimumab in poor-prognosis unresectable hepatocellular carcinoma: Phase IIIb single-arm SIERRA study.

New evidencehepatocellular carcinoma
Clinical takeawaySTRIDE (tremelimumab 300 mg once plus durvalumab 1500 mg every 4 weeks) was tolerable in patients usually excluded from trials, with grade 3/4 related adverse events in 19.8% (95% CI 12.9-28.5) at 6 months and an objective response rate of 14.4%. SIERRA is single-arm with no comparator, so it shows feasibility, not benefit over alternatives or best supportive care.
What it foundSTRIDE regimen showed a 14.4% ORR (95% CI 8.5-22.4) and 19.8% Grade 3/4 PRAEs ≤6 months (95% CI 12.9-28.5) in poor-prognosis uHCC patients.
ContextThis literature reports that the dual immune checkpoint inhibitor regimen STRIDE shows promise as a first-line treatment for poor-prognosis unresectable hepatocellular carcinoma, based on early safety data from the phase IIIb SIERRA study.
No standard claimed for this paper

Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.

Chan SL … Rimassa L · Journal of Hepatology · IF 40.1 · PubMed ↗Permalink
← Read the whole of issue №15 Every paper GI Signals surfaces gets a page like this one. All issues